Expand Document  |  Expand Chapter  |  Full TOC  |  Printable HTML version
Health Reform and Drug Financing. Selected Topics - Health Economics and Drugs Series, No. 006
(1998; 49 pages) [French] [Spanish]
Table of Contents
View the documentAcknowledgements
View the documentExecutive summary
Open this folder and view contents1. Introduction
Open this folder and view contents2. Financing reforms
Open this folder and view contents3. Affordability and efficiency
Open this folder and view contents4. Organizational reforms
View the documentConclusions
View the documentReferences
View the documentBack Cover
 

References

1.

Antezana F, Velasquez G. Drugs and health sector reform. WHO Task Force on Health Economics. Geneva: World Health Organization; 1996. WH0/TFHE/96.2.



2.

Antezana F, Velasquez G. Drugs and health sector reform. Paper presented and revised at the Fifth International Meeting on Health Economics (Buenos Aires, Argentina, 24-26 April 1996) and at the National Seminar on Health Sector Reform and Drugs (Managua, Nicaragua, 29-30 April 1996). 1996.



3.

Arango JI, Carlevaro P, Velasquez G. The public and private circuits for the distribution of drugs in the Chilean health system. Written for UNICEF and the WHO Action Programme on Essential Drugs. Geneva: World Health Organization; 1996. Health economics and drugs, DAP Series N° 2. WHO/DAP/96.1.



4.

Ballance R, Pogány J, Forstner H. The world’s pharmaceutical industries. An international perspective on innovation, competition and policy. Prepared for United Nations Industrial Development Organization. Aldershot, UK: Edward Elgar Publishing Limited; 1992.



5.

Bennett S, Ngalande-Banda E. Public and private roles in health: a review and analysis of experience in sub-Saharan Africa. Division of Strengthening of Health Services. Geneva: World Health Organization; 1994.



6.

Bennett S, Muraleedharan VR. Personal communication on Tamil Nadu Medical Services Corporation. 1997.



7.

Broun D. Procurement of pharmaceuticals in World Bank projects (HRO working papers). Washington, D C: World Bank; 1998. HROW 38.



8.

Cassels A. Health sector reform: key issues in less developed countries. Geneva: World Health Organization; 1995. Discussion paper N° 1. WHO/SHS/NHP/95.7.



9.

Creese A L, Kutzin J. Lessons from cost-recovery in health. Forum on health sector reform. Discussion paper N° 2. Geneva: World Health Organization; 1995.



10.

Dumoulin J, Kaddar M, Velasquez G. Access to drugs and finance. Basic economic and financial analysis. Geneva: World Health Organization; 1991. WHO/DAP/91.5.



11.

Frenk J. Comprehensive policy analysis for health system reform. In: Health Policy Review. 1995; 32: 257-77.



12.

GAO. Prescription drugs: spending controls in four European countries. Report to the Chairman, Special Committee on Ageing, U.S. Senate. Washington, D C: United States General Accounting Office; 1994. GAO/HEHS-94-30.



13.

GAO. Prescription drugs: companies typically charge more in the United States than in the United Kingdom. Report to the Chairman, Subcommittee on Health and the Environment, Committee on Energy and Commerce, House of Representatives. Washington, D C: United States General Accounting Office; 1994. GAO/HEHS-94-29.



14.

Gilson L, Dave Sen P, Mohammed S, Mujinja P. The potential of health sector non-governmental organizations: policy options. In: Health Policy Plan. 1994; 9 (1): 14-24.



15.

Gilson L, Russell S, Buse K. The political economy of user fees with targeting: developing equitable health financing policy. In: Journal of International Development. 1995; 7: 369-401.



16.

Haaijer-Ruskamp FM, Dukes MNG. Drugs and money. The problem of cost containment. 6th edition. Groningen: WHO Collaborating Centre for Clinical Pharmacology and Drug Policy Science and Pharmaceuticals Unit, World Health Organization, Regional Office for Europe. STYX Publications; 1991.



17.

Hogerzeil HV, Couper MR, Gray R. Guidelines for drug donations. In: BMJ. 1997; 314: 737-40.



18.

Lexchin J. Pharmaceutical promotion in the third world. In: The Journal of Drug Issues. 1992; 22 (2): 417-53.



19.

McPake B, Hanson K, Mills A. Community financing of health care in Africa: an evaluation of the Bamako Initiative. In: Soc Sci Med. 1993; 36 (11): 1383-95.



20.

McPake B, Ngalande-Bande E. Contracting out health services in developing countries. In: Health Policy Plan. 1994; 9 (1): 25-30.



21.

Mossialos E, Ranos C, Abel-Smith B, et al. Cost containment, pricing and financing of pharmaceuticals in the European Community: the policy-makers’ view. Athens, Greece: LSE Health and Pharmetrica S.A.; 1994.



22.

Möller H, Pharasi B, Summers RS. Evaluation of pharmaceutical services in the Northern Transvaal Province. School of Pharmacy, MEDICOS Pharmacy Project and Centre for Health Policy, University of the Witwatersrand. South Africa: Medical University of Southern Africa; 1994.



23.

MSH/WHO/DAP. Managing drug supply, 2nd edition. Hartford, CT: Kumarian Press; 1997. Management Sciences for Health in collaboration with World Health Organization, Action Programme on Essential Drugs. Edited by Quick JD, Rankin J, Laing RO, O’Connor R, Hogerzeil HV, Dukes MNG, and Garnet A.



24.

Murray CJL, Lopez AD, editors. Global comparative assessments in the health sector: disease burden, expenditures, and intervention packages. Geneva: World Health Organization; 1994.



25.

Murray CJL, Govindaraj R, Musgrove P. National health expenditures: a global analysis. Murray C, Lopez A, editors. In: Global comparative assessments in the health sector: disease burden, expenditures and intervention packages. Geneva: World Health Organization; 1994.



26.

Nolan B, Turbat V. Cost recovery in public health services in sub-Saharan Africa. EDI Technical Materials. Washington, D C: World Bank; 1995.



27.

Normand C, Weber A. Social health insurance: a guidebook for planning. Geneva: World Health Organization; 1994. WHO/SHS/94.3.



28.

Pannenberg O. The World Bank and pharmaceuticals. Presentation at the meeting on Improving International Coordination in the Pharmaceutical Sector, Stockholm, September 1996. World Bank, Human Development Department; 1996.



29.

Peabody JW. Economic reform and health sector policy: lessons from structural adjustment programmes. In: Soc Sci Med. 1996; 43 (5): 823-35.



30.

Rankin J. Engaging the private sector in the public pharmaceutical system. Conference presentation, 8-11 October 1995. Sydney: International Conference on National Medicinal Drug Policies; 1995.



31.

Redwood H. Price regulation and pharmaceutical research: the limits of co-existence. Felixstow, Suffolk, UK: Oldwicks Press Limited; 1993.



32.

Redwood H. Public policy trends in drug pricing and reimbursement in the European Community. In: PharmacoEconomics. 1994; 6: 3-10.



33.

Sarmiento AZ. Alternative drug pricing policies in the Americas. Geneva: Action Programme on Essential Drugs, World Health Organization; 1995. Health economics and drugs, DAP Series N° 1. WHO/DAP/95.6.



34.

Shaw PR, Ainsworth M. Financing health services through user fees and insurance. World Bank discussion paper N° 294. 1996.



35.

Shaw PR, Griffin CC. Financing health care in sub-Saharan Africa through user fees and insurance. Washington, D C: World Bank; 1995.



36.

Summers RS. Personal communication. 1996.



37.

Weeda G. Personal communication. 1995.



38.

Wertheimer AI, Grumer SK. Overview of international pharmacy pricing. In: PharmacoEconomics. 1992; 2: 449-55.



39.

WHO. Evaluation of recent changes in the financing of health services. Report of a WHO study group. In: WHO Technical Report Series N° 829. Geneva: World Health Organization, 1993; p. 1-74.



40.

WHO. Guidelines for drug donations. WHO, UNHCR, ICRC, IFRC, MSH, WCC, OXFAM. Geneva: World Health Organization; 1996. WHO/DAP/96.2.



41.

WHO/DAP. Estimating drug requirements: a practical manual. Geneva: World Health Organization; 1988.



42.

WHO/DAP. Informal consultation on evolving public-private roles in the pharmaceutical sector. 15-18 April 1996. Geneva: World Health Organization; 1996.



43.

WHO/DAP. Discussion paper on public-private roles in the pharmaceutical sector (draft, 23 February 1996). Geneva: World Health Organization; 1996.



44.

WHO/DAP. Comparative national drug policies. Report of a meeting. Geneva: World Health Organization; 1996.



45.

WHO/DAP. Competitive mechanisms for public drug supply: options, issues, and cautions (working draft). Geneva: World Health Organization; 1997.



46.

WHO/DAP. Global comparative pharmaceutical expenditures. Geneva: World Health Organization; 1997. Health economics and drugs, DAP Series N° 3 (in preparation).



47.

WHO/EURO. Drug pricing systems in Europe: an overview. Programme for Pharmaceuticals in CCEE/NIS. Copenhagen: World Health Organization Regional Office for Europe; 1994.



48.

WHO/SHS. Experience with organizational and financing reform in the health sector. Geneva: World Health Organization; 1995. WHO/SHS/CC/94.3.



49.

Wilkes MS, Doblin BH, Shapiro MF. Pharmaceutical advertisements in leading medical journals: Experts’ assessments. In: Annals of Internal Medicine. 1992; 116: 912-9.



50.

World Bank. World development report 1993. Investing in health. New York, NY: Oxford University Press; 1993.

 

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: August 29, 2014